전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,373 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleWomen's Hospital School Of Medi…Phase 2

PD-1 inhibitor， bevacizumab (PD-1 inhibitor， bevacizumab)

Gestational Trophoblastic Neoplasia · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#GestationalTrophoblasticNeoplasi+1
Trials 1Status Active
AntibodyLimited DatastaleGuangzhou Anjie Biomedical Tech…Phase 2

PD-1 mAb (PD-1 mAb)

Lung Neoplasm Malignant; Non-small Cell Lung Cancer · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#LungNeoplasmMalignant+2
Trials 1Status Active
CGTLimited Datastalejiuwei cuiPhase 1

PD-1-M1-NK Cells (PD-1-M1-NK Cells)

Advanced Gastric or Colorectal Cancer · PD-1

#PD-1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleZhongda HospitalPreclinical

PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab)

Hepatocellular Carcinoma · PD-1

#PD-1#Antibody#Preclinical#monoclonal-antibody#HepatocellularCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastalePfizerPhase 1

nivolumab (Opdivo, TTI-621, PF-07901800, PF-07901800 (TTI-621) plus Nivolumab)

Hematologic Malignancies; Solid Tumor · Hematologic Malignancies

#HematologicMalignancies#Antibody#Phase1#monoclonal-antibody#SolidTumor+1
Trials 1Status Discontinued
AntibodyLimited DatastalePfizerPhase 1

PF-07901800 (TTI-621, PF-07901800, PF-07901800 (TTI-621) plus Rituximab)

Hematologic Malignancies; Solid Tumor · Hematologic Malignancies

#HematologicMalignancies#Antibody#Phase1#monoclonal-antibody#SolidTumor+1
Trials 1Status Discontinued
AntibodyLimited DatastaleChinese PLA General HospitalPhase 1

PIN+sintilimab (PIN+sintilimab)

Colorectal Cancer; Adult · Colorectal Cancer

#ColorectalCancer#Antibody#Phase1#monoclonal-antibody#Adult+1
Trials 1Status Recruiting
CGTLimited DatastalePrecigen, IncPhase 1

PRGN-3005 UltraCAR-T cells (PRGN-3005 UltraCAR-T cells)

Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Changzheng HospitalPhase 1

BRL-302 (PSMA-UCAR T, PSMA-UCAR T (BRL-302))

Metastatic Prostate Cancer; Castration-resistant Prostate Cancer · PSMA

#PSMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleSCRI Development Innovations, L…Phase 1

PTK787/ZK222584 and Bevacizumab (PTK787/ZK222584 and Bevacizumab)

Refractory Malignancy; Advanced Malignancies · FRα

#FR#Antibody#Phase1#monoclonal-antibody#RefractoryMalignancy+2
Trials 1Status Active
AntibodyLimited DatastaleAbbVie (prior sponsor, Abbott)Phase 3

Palivizumab (Palivizumab)

Respiratory Syncytial Virus Infection · Respiratory Syncytial Virus Infection

#RespiratorySyncytialVirusInfecti#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 1Status Active
AntibodyLimited DatastaleJanssenApproved

Palmitoleic Acid + Infliximab (Palmitoleic Acid + Infliximab)

Crohn's Disease · Crohn's Disease

#CrohnsDisease#Antibody#Approved#monoclonal-antibody#Janssen
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Pan-T booster co-expressing MSLN CAR T cell (Pan-T booster co-expressing MSLN CAR T cell)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
AntibodyLimited DatastaleChinese PLA General HospitalPhase 2

Pancreatic cancer: Tunlametinib + cetuximab β (Pancreatic cancer: Tunlametinib + cetuximab β)

Treatment for Advanced Colorectal Cancer; Treatment for Advanced Pancreatic Cancer · Treatment for Advanced Colorectal Cancer

#TreatmentforAdvancedColorectalCa#Antibody#Phase2#monoclonal-antibody#TreatmentforAdvancedPancreaticCa+1
Trials 1Status Recruiting
AntibodyLimited DatastaleChinese PLA General HospitalPhase 2

Pancreatic cancer: Tunlametinib +Nimotuzumab (Pancreatic cancer: Tunlametinib +Nimotuzumab)

Treatment for Advanced Colorectal Cancer; Treatment for Advanced Pancreatic Cancer · Treatment for Advanced Colorectal Cancer

#TreatmentforAdvancedColorectalCa#Antibody#Phase2#monoclonal-antibody#TreatmentforAdvancedPancreaticCa+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAmgenPhase 2

ABX-EGF (Panitumumab, Panitumumab (ABX-EGF))

Colorectal Cancer; Non-Small Cell Lung Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#Non-SmallCellLungCancer+1
Trials 1Status Active
CGTLimited DatastaleSeattle Children's HospitalPhase 1

3rd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells))

Neuroblastoma; Ganglioneuroblastoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Pegylated Liposomal Doxorubicin (Doxil, Pegylated Liposomal Doxorubicin, Pegylated Liposomal Doxorubicin (Doxil) and Rituximab)

Non-Hodgkin's Lymphoma; Burkitt Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#monoclonal-antibody#BurkittLymphoma+1
Trials 1Status Discontinued
CGTLimited DatastalePell Bio-Med Technology Co., Lt…Preclinical

Pell's lentiviral-based gene-edited immune cell therapy (Pell's lentiviral-based gene-edited immune cell therapy)

Diffuse Large B Cell Lymphoma; Large B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
ADCLimited DatastaleMerckPhase 2

PEV (Pembrolizumab & Enfortumab Vedotin, Pembrolizumab & Enfortumab Vedotin (PEV))

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#ADC#Phase2#antibody-drug-conjugate#Merck
Trials 1Status Recruiting

54 / 69 pages

← PreviousNext →